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        MHC class I molecules present short peptides 
at the cell surface, typically 8  –  11 mers, for scru-
tiny by CD8 T lymphocytes (  1, 2  ). Generation 
of peptide  –  MHC I complexes is initiated by 
proteasomal degradation of source proteins in 
the cytosol (  3  ). Peptides generated by the pro-
teasome are translocated in the endoplasmic re-
ticulum, where they are subjected to N-terminal 
trimming, and then incorporated in MHC I 
proteins and exported at the cell surface (  4  –  7  ). 
Presentation of microbial peptides by MHC I is 
required to elicit CD8 T cell responses against 
intracellular pathogens (  8  ). Under steady-state 
conditions, i.e., in the absence of infection, cell 
surface MHC I molecules are associated solely 
with self-peptides. These peptides, collectively 
referred to as the MHC class I peptide (MIP) 
repertoire (  9  ), play vital roles. They shape the 
repertoire of developing thymocytes (  10, 11  ), 
transmit survival signals to mature CD8 T cells 
(  12  ), amplify responses against intracellular path-
ogens (  13  ), allow immunosurveillance of neo-
plastic cells ( 14  ), and infl  uence mating preferences 
in mice ( 15  ). The MIP repertoire is also involved 
in immunopathology because it can be targeted 
by autoreactive T cells that initiate autoimmune 
diseases and alloreactive T cells that cause graft 
rejection and graft-versus-host disease (  16, 17  ). 
  Despite the tremendous importance of the 
MIP repertoire, we know very little about its 
genesis and molecular composition. Proteomic 
analysis of the MIP repertoire is a daunting task 
because estimates suggest that it encompasses 
thousands of peptides that are present in low copy 
numbers per cell (  1, 18  ). Each MHC molecule 
recognizes peptides through a broadly defi  ned 
consensus motif of amino acids serving as anchors 
to the appropriate binding pockets on the MHC 
molecules. Such motifs were fi  rst established by 
pool Edman sequencing of unfractionated pep-
tide mixtures eluted from MHC mole  cules (  19  ). 
Direct biochemical characterization of specifi  c 
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  Under steady-state conditions, major histocompatibility complex (MHC) I molecules are 
associated with self-peptides that are collectively referred to as the MHC class I peptide 
(MIP) repertoire. Very little is known about the genesis and molecular composition of the 
MIP repertoire. We developed a novel high-throughput mass spectrometry approach that 
yields an accurate defi  nition of the nature and relative abundance of unlabeled peptides 
presented by MHC I molecules. We identifi  ed 189 and 196 MHC I  –  associated peptides from 
normal and neoplastic mouse thymocytes, respectively. By integrating our peptidomic data 
with global profi  ling of the transcriptome, we reached two conclusions. The MIP repertoire 
of primary mouse thymocytes is biased toward peptides derived from highly abundant 
transcripts and is enriched in peptides derived from cyclins/cyclin-dependent kinases and 
helicases. Furthermore, we found that     25% of MHC I  –  associated peptides were differen-
tially expressed on normal versus neoplastic thymocytes. Approximately half of those 
peptides are derived from molecules directly implicated in neoplastic transformation (e.g., 
components of the PI3K  –  AKT  –  mTOR pathway). In most cases, overexpression of MHC I 
peptides on cancer cells entailed posttranscriptional mechanisms. Our results show that 
high-throughput analysis and sequencing of MHC I  –  associated peptides yields unique 
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  sequencing platform provide valuable insights for the identifi  -
cation of immunogenic tumor-associated epitopes? 
    RESULTS   
  Experimental approach for the identifi  cation 
and quantifi  cation of MHC I  –  associated peptides 
  Mild acid elution (MAE) of MHC I  –  associated peptides from 
living cells presents several advantages over immunoprecipita-
tion of peptide  –  MHC I complexes. Because it involves fewer 
purifi  cation steps and no detergents, MAE yields     10 times 
more MHC I  –  associated peptides than the latter and intro-
duces no bias linked to preferential loss of low-affi   nity peptides 
(  37  –  39  ). However, MAE has never been used for high-
throughput sequencing of the MIP repertoire because it is as-
sumed that eluted peptides contain not only MHC I –  associated 
peptides, but also   “  contaminant  ”   peptides. We reasoned that 
this problem could be overcome by using MHC I  –  defi  cient 
cells as a negative control. Because     2-microglobulin (    2m) 
is essential for formation of stable peptide  –  MHC I complexes, 
    2m-defi  cient cells are MHC I defi  cient. We therefore com-
pared peptides eluted from three cell populations, as follows: 
WT EL4 thymoma cell line, a     2m-defi  cient EL4 mutant cell 
line (C4.4-25       ), and C4.4-25        cells transfected with a genomic 
clone of murine     2m (E50.16  +  ) (  40  ). Flow cytometry analysis 
showed that expression of H2D  b  , H2K  b  , and Qa2 MHC I 
molecules were abrogated in     2m-defi  cient EL4 cells, but were 
restored in     2m transfectants (  Fig. 1 A  ).   
  Samples obtained by MAE of peptides from 8   ×   10  7   cells 
were analyzed using an on-line 2D-nanoLC-MS system (see 
Materials and methods for more details). Each individual LC-
MS run was visualized as a three-dimensional map where each 
isotopic profi  le (dot) corresponds to a given ion that is defi  ned 
by its specifi  c abundance, m/z, and retention time coordinates 
(  Fig. 1 B  ). We fi  rst assessed the reproducibility of data ob-
tained with our method using peptide eluates from WT EL4 
cells. We found that 95% of peptide ions showed a variation 
of less than   ±  1.4- and   ±  2.2-fold in abundance across 2D-
nanoLC-MS instrumental and biological replicates, respectively 
(Fig. S1, available at http://www.jem.org/cgi/content/full/
jem.20071985/DC1). Therefore, peptides were considered 
to be diff  erentially expressed when the fold diff  erence in 
abundance was   ≥  2.5 (P   <   0.05). We next compared profi  les 
from WT and     2m-defi  cient EL4 cells. Contour profi  les ob-
tained after computational analyses showed a higher level of 
peptide complexity for WT compared with     2m-defi  cient 
EL4 cells (  Fig. 1 B  ). We assessed the proportion of MHC I  –
  associated versus contaminant peptides using in-house pep-
tide detection software (unpublished data). To identify and 
defi  ne individual peptide clusters, peptide lists generated by 
Mass Sense were compared through replicate injections from 
both WT- and     2m        mutant-derived samples using segmen-
tation analyses with hierarchical clustering. Heat map repre-
sentation was used to visualize diff  erences in peptide cluster 
expression between WT- and     2m        mutant  –  derived sam-
ples (  Fig. 1 B  ). Peptides that were recovered only from WT 
EL4 cells were considered to be part of the MIP repertoire. 
MHC I  –  associated peptides has typically involved immuno-
affi   nity purifi  cation of MHC molecules after cell lysis, frac-
tionation of the peptides by chromatography, and sequencing, 
initially by Edman  ’  s method and, more recently, by mass spec-
trometry (MS). Refi  nements in MS methods pioneered by 
Hunt et al. and Falk et al. represented major progress and led 
to the characterization of several MHC I  –  associated peptides 
(  18, 20, 21  ), in spite of limitations such as low peptide yield, 
preferential loss of peptides with low affi   nity for MHC I, and 
contamination of the MHC molecules by cellular debris and 
detergents (  22, 23  ). 
  Two high-throughput strategies were therefore imple-
mented to provide comprehensive molecular defi  nition of the 
MIP repertoire. The fi  rst is based on transfection of cell lines 
with expression vectors coding soluble secreted MHCs (lack-
ing a functional transmembrane domain) and elution of pep-
tides associated with secreted MHCs (  24, 25  ). This interesting 
approach improves MHC I peptide recovery, but presents 
some limitations, as follows: (a) it cannot be used on freshly 
explanted cells; (b) cell transfection by itself may perturb the 
MIP repertoire (  26  ); and (c) the MIP repertoire associated 
with soluble MHC corresponds to the repertoire of peptides 
that can bind the transfected MHC allele (what   “  can be pre-
sented  ”  ), but not necessarily to peptides that are normally 
presented at the cell surface (what   “  is presented  ”  ). The sec-
ond approach hinges on chemical or metabolic labeling to 
provide quantitative profi  les of MHC I  –  associated peptides 
(  9, 27  –  29  ). Although chemical derivatization suff  ers from vari-
able modifi  cation yields and unexpected side reaction prod-
ucts, metabolic labeling is only applicable to certain MHC I 
allelic products and to cell culture model systems (  30, 31  ). 
Nonetheless, high-throughput peptide sequencing analyses 
have provided crucial insights into the structure of the MIP 
repertoire. First, the source proteins for the MIP repertoire are 
found in almost every compartment of the cell (  25  ). Second, 
only a limited correlation is observed between the amounts of 
the MHC I  –  associated peptides presented by cells and the rela-
tive expression of source proteins from which these peptides 
are derived (  28  ). A likely explanation for this discrepancy is 
that the MIP repertoire preferentially derives from defective 
ribosomal products (DRiPs) and short-lived proteins relative 
to slowly degraded proteins (  2, 32, 33  ). Third, for peptides 
diff  erentially expressed on normal versus neoplastic cells, no 
clear correlation was found between mRNA levels and corre-
sponding MHC peptide levels (  9  ). 
  The goal of our work was to understand the structure and 
genesis of the MIP repertoire. In accordance with a recent 
  advocacy for   “  systems immunology  ”   (  34  ), we used novel bio-
informatics tools based on peptide mapping and segmentation 
to obtain a global and accurate quantifi  cation of native unla-
beled peptides present in the MIP repertoire (unpublished data) 
(  35, 36  ). In particular, we addressed four specifi  c questions. Does 
the MIP repertoire refl  ect the composition of the transcrip-
tome? Are some gene families overrepresented in the MIP rep-
ertoire? What is the impact of neoplastic transformation on the 
MIP repertoire? Can a high-throughput, unlabeled-peptide  –JEM VOL. 205, March 17, 2008 
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    Figure 1.         Experimental design for identifi  cation and relative quantifi  cation of native unlabeled MHC I  –  associated peptides  . (A) Cell surface 
MHC I expression on EL4 WT,    2m       mutant, and    2m +   transfectant cell lines. Cells were stained with antibodies against H2D  b ,  H2K b  , and Qa2 (black) or 
the corresponding isotype control antibody (gray). (B) Peptides obtained by MAE were analyzed by on-line 2D-nanoLC-MS (three biological replicates for 
each cell population). Contour profi  les of m/z versus retention time versus intensity were used to visualize differences between MS profi  les (middle). 
A logarithmic intensity scale distinguishes between low (dark red) and highly (bright yellow) abundant species. Examples of peptides that were differen-
tially expressed (blue line) or not (green line) between WT and    2m       EL4 cells are highlighted in boxes. (bottom) Heat map representation shows 
differential peptide expression between WT and    2m       EL4 cells where each horizontal line corresponds to a unique peptide cluster (  n   = 3,716). A loga-
rithmic scale depicts peptides that are expressed at high (red) or low (green) level in each cell population. (C) Volcano plot representation showing 
reproducibly detected peptide ions across three replicate analyses. Peptide clusters (  n   = 1,236) highlighted in dashed box were considered as class I  – 
restricted (P   ≤   0.05; fold change   ≥   5). Peptides that were sequenced by MS/MS are represented by colored dots: green for contaminants, and blue for 
MHC  I – associated  peptides.   598 GENESIS OF THE MHC CLASS I PEPTIDE REPERTOIRE | Fortier et al.
we analyzed peptides recovered from E50.16  +   cells (    2m-
defi  cient EL4 cells transfected with a genomic clone of mu-
rine     2m). As expected, we observed that 95% of MHC I 
peptides were expressed at the cell surface of     2m  +   transfec-
tants. Absence of a few MHC I peptides on     2m transfectants 
is probably explained by the lower expression of H2D  b   and 
H2K  b   on     2m transfectants compared with WT cells (  Fig. 1 A  ). 
For the 178 sequenced MHC I  –  associated peptides, relative 
abundance in the three EL4 cell variants (WT,     2m        mutants, 
and     2m  +   transfectants) is presented in Table S1 (available at 
http://www.jem.org/cgi/content/full/jem.20071985/DC1). 
Data for a representative set of peptides is shown in   Table I  .   
Notably, although MHC I peptides were 8  –  13 mers, the 
length of contaminant peptides was more variable, ranging 
from 6 to 26 amino acids with a median value of 13 residues 
(unpublished data). 
  Defi  nition of the MIP repertoire presented by discrete
MHC I allelic products 
  Large databases of MHC I peptides and computational bind-
ing methods are now part of emerging biomedical resources 
(  42  –  45  ). Information in these databases concerns mainly, 
though not exclusively, viral and bacterial-derived peptides 
presented by MHC I allelic products in humans and mice. 
Each MHC I peptide in Table S1 was manually classifi  ed 
according to restriction size and binding motif favored by 
D  b  , K  b  , Qa1, and Qa2 class I molecules ( 19, 46, 47 ). From 178 
MHC I peptides identifi  ed from variant EL4 cell lines, 92% 
were presented by classical MHC Ia allelic products H2D  b   and 
H2K  b  , and 8% were presented by MHC Ib molecules Qa1 
and Qa2 (  Fig. 2 A   and Table S2, available at http://www
.jem.org/cgi/content/full/jem.20071985/DC1).   When viewed 
Because     2m-defi  cient cells express low amounts of incom-
plete MHC I molecules at the cell surface (  41  ), we also con-
sidered that peptides signifi   cantly more abundant on WT 
relative to     2m-defi  cient cells were MHC I associated. In the 
latter case, we used a very stringent criterion; to be consid-
ered as MHC I associated, a peptide had to be at least fi  ve 
times more abundant on WT relative to     2m-defi  cient cells. 
Out of 3,716 unique peptide clusters that were reproducibly 
detected across three biological replicates, 1,487 peptide clus-
ters were overexpressed or uniquely detected within the WT 
EL4 sample. Thus, we estimated that     40% of acid-eluted 
materials correspond to specifi  c-MHC I peptides. 
  We obtained MS/MS assignments for 881 of the 3,716 
peptide clusters, all of which had a characteristic fragmenta-
tion associated to peptide backbone cleavages. Although 
these identifi  cations correspond to 24% of the entire ion pop-
ulation detected, other MS/MS spectra were assigned to mod-
ifi  ed residues, de novo peptide sequences, or spectra of poor 
quality. Peptide coordinates were computationally related to 
their corresponding sequenced peptides. Out of 881 sequenced 
peptides, 383 had a consensus motif for H2D  b  , H2K  b  , Qa1, 
or Qa2 MHC I molecules. Stringent validation criteria were 
next applied to select peptide ions showing mass accuracy of 
  <  30 parts per million (ppm), with MS/MS spectra display-
ing consistent sets of b- and/or y-type fragment ion series 
corresponding to the MHC I peptide sequence. This manual 
validation enabled the identifi  cation of 178 unique MS/MS 
corresponding to MHC I  –  associated peptides: 158 were de-
tected uniquely in eluates from WT EL4 cells, whereas 20 were 
overexpressed at least 5-fold on WT relative to     2m-defi  -
cient EL4 cells (  Fig. 1 C  ). To confi  rm that diff  erences between 
WT and     2m-defi  cient EL4 cells were truly     2m dependent, 
    Table I.    Relative abundance of a representative set of peptides recovered in eluates from three EL4 cell variants: WT,    2m      
mutants, and    2m +   transfectants 
Gene ID Gene symbol Sequence WT     2m  −      2m  +   WT/    2m  − 
20848   Stat3 ATLVFHNL 4,023,137 12,000 6,208,130 335
66165   Bccip KAPVNTAEL 1,741,908 12,000 998,607 145
15016   H2-Q5 AMAPRTLLL 5,436,819 12,000 12,941,105 453
67755   Ddx47 KTFLFSATM 70,059 12,000 289,017 6
12649   Chek1 TGPSNVDKL 6,545,497 112,308 14,733,333 58
267019   Rps15a VIVRFLTV 514,406 12,000 12,000 43
71745   Cul2 VINSFVHV 67,372 12,000 244,370 6
233489   Picalm NGVINAAFM 265,420 12,000 438,191 22
26413   Mapk1 VGPRYTNL 39,166,667 149,969 45,832,060 261
108655   Foxp1 QQLQQQHLL 705,266 12,000 1,054,408 59
170755   Sgk3 YSIVNASVL 255,048 38,491 151,335 7
326622   Upf2 SAVIFRTL 244,247 12,000 1,102,686 20
12877   Cpeb1 SMLQNPLGNVL 185,198 12,000 528,268 15
94176   Dock2 SMVQNRVFL 895,081 12,000 671,603 75
16913   Psmb8 GGVVNMYHM 3,332,728 12,000 2,116,510 277
Gene ID and Gene Symbol description refer to National Center for Biotechnology Information gene entries. Intensities for each EL4 variant cell line correspond to the average 
MS signal calculated from triplicate experiments. An intensity threshold value of 12,000 was fi  xed when no signal was detected. To be considered as MHC I associated, a 
peptide had to be at least fi  ve times more abundant on WT relative to    2m-defi  cient cells.JEM VOL. 205, March 17, 2008 
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protein of 400 amino acids contains 392 nonapeptide sequences). 
We then asked how each peptide that we had sequenced 
by MS/MS would rank relative to other peptides from its 
source protein. Remarkably, 91% of H2D  b  -associated peptides 
eluted from EL4 cells ranked in the top 1% in terms of H2D  b   
binding affi   nity (  Fig. 2 C   and Table S2). Similar results were 
obtained from the SYFPEITHI database (unpublished data). 
That some peptide sequences predicted to be top MHC I 
binders were not found in the MIP repertoire of EL4 cells is 
not surprising. This means either that proteases involved in 
MHC I processing do not generate these specifi  c   “  degradation 
products  ”   or that they are present in subthreshold amounts. 
For H2K  b  , 85% of peptides ranked in the top 5% for pre-
dicted H2K  b   binding affi   nity (  Fig. 2 C   and Table S2). These 
data support the concept that MHC I binding affi   nity plays a 
dominant role in shaping the content of the MIP repertoire. 
  Discrimination between MHC I  –  associated peptides 
and contaminant peptides using bioinformatic tools 
  In the aforementioned experiments, we used     2m-defi  cient 
cells as negative control to discriminate MHC I  –  associated 
peptides from contaminant peptides. The need for an MHC I  –
  defi  cient negative control would nevertheless represent a 
signifi  cant hurdle for high-throughput sequencing of the 
MIP repertoire of primary cells. We therefore asked whether 
bioinformatic tools could be used to identify MHC I  –  associ-
ated peptides among a peptide mixture obtained by MAE. 
We fi  rst ranked the 164 H2D  b  - and H2K  b  -associated pep-
tides eluted from EL4 cells as a function of their MHC bind-
ing score estimated with smm and SYFPEITHI algorithms 
(  Fig. 3  , red bars).   We found that     97% of MHC I  –  associated 
peptides were scored below an smm binding threshold of 
1,000 nM (IC  50  ) and above a SYFPEITHI binding threshold 
of 22 for H2D  b   and 13 for H2K  b   (  Fig. 3  ). The aforemen-
tioned thresholds therefore provided a 3% false-negative rate 
(3% of MHC I  –  associated peptides were wrongly classifi  ed as 
contaminants). To estimate the false-positive rate obtained 
with these thresholds, we analyzed the 215 contaminant pep-
tides eluted from EL4 cells representing high-quality assign-
ment (Mascot score   >  45, mass accuracy   <  30 ppm, MS/MS 
manually inspected) from a list of 498 candidates that were 
not signifi  cantly overexpressed on WT relative to     2m-defi  -
cient EL4 cells. Only 56 out of the 215 contaminant peptides 
had the canonical length for binding H2D  b   or H2K  b  , and 
very few of them satisfi  ed our smm and SYFPEITHI thresh-
olds (  Fig. 3  , blue bars). Overall, the false-positive rate was 
  <  2% (  <  2% of contaminants were wrongly classifi  ed as MHC I  – 
associated peptides). Similar results were obtained for Qa2 
peptides using the Rankpep algorithm with a binding thresh-
old of 120. We synthesized nine peptides across the pre-
dicted affi   nity spectrum and tested their ability to bind H2K  b   
or H2D  b  . Peptides classifi  ed as MHC I associated according 
to their smm score did bind to MHC I, whereas peptides 
classifi  ed as contaminants did not (Fig. S2). These experi-
mental data further validate bioinformatic discrimination be-
tween MHC I  –  associated peptides and contaminant peptides. 
in toto, peptide pools presented by H2D  b  , H2K  b  , and Qa2 
displayed the canonical binding motifs documented for these 
MHC I molecules (  Fig. 2 B  ). 
  A priori, two factors may determine whether specifi  c 
peptides are presented by MHC I: peptide affi   nity for MHC 
molecules and the processing of source proteins along the 
MHC I presentation pathway. Protein attributes that are rel-
evant to MHC I processing include rates of protein transla-
tion, DRiP formation, and degradation (  32, 33, 48, 49  ). To 
evaluate the importance of peptide binding affi   nity, each of 
the 164 source proteins of peptides presented by H2D  b   (  n   = 96) 
or H2K  b   (  n   = 68) was analyzed with the smm algorithm. We 
scored and ranked the predicted binding affi   nity of all peptides 
from individual proteins for H2D  b   or H2K  b   (for example, a 
    Figure 2.         Allelic distribution and binding scores of 178 MHC I  –
  associated peptides eluted from EL4 cells  . (A) Pie chart shows distri-
bution of 178 MHC I  –  associated peptides eluted from EL4 cells. The smm, 
SYFPEITHI (H2D  b   and  H2K b  ), and Rankpep (Qa2) computational models 
were used to link individual peptides to MHC I allelic products. (B) Logo 
showing the profi  le motif for peptides presented by H2-D  b ,  H2-K b ,  and 
Qa2 molecules. Acidic (red), basic (blue), hydrophobic (black), and neutral 
(green) amino acids are illustrated. (C) Individual source proteins for pep-
tides presented by H2D  b   and  H2K b   ( n   = 164) were entered in the smm 
binding algorithm. We assessed the predicted MHC I binding affi  nity of all 
peptides contained in individual proteins. Pie charts show the proportion 
of peptides eluted from EL4 cells that ranked in the top 1% (blue), top 5% 
(green), top 10% (yellow), or below the 90th percentile of peptides (red).     600 GENESIS OF THE MHC CLASS I PEPTIDE REPERTOIRE | Fortier et al.
transcripts: (a) those encoding MHC I peptides eluted from 
primary thymocytes (Table S3), and (b) 36,182 transcripts 
encoded by the mouse genome (  50  ). We found a dramatic 
enrichment in highly abundant mRNAs among transcripts 
coding for MHC I peptides (  Fig. 4, B and C  ). Thus, al-
though 9% of total mRNAs are expressed at high levels, 42% 
of those coding MHC I peptides did so (  Fig. 4 C  ). Con-
versely, 62% of total mRNAs showed low abundance, but 
only 20% of those coding MHC I peptides were expressed at 
low levels. Nonetheless, some MHC I peptides are coded by 
low abundance mRNAs (  Fig. 4, B and C  ). We hypothesized 
that low abundance mRNAs may contribute to the MIP 
repertoire because they code peptides with very high affi   nity 
for MHC I. Our data did not support that assertion. We 
found no correlation between the computed MHC I binding 
affi   nity of peptides and the abundance of their mRNAs 
(  Fig. 4 D  ). MHC I peptides derived from low-abundance 
transcripts did not display superior computed MHC binding 
affi   nity. Although the ability to detect MHC I peptides is 
limited by the MS sensitivity (high attomole range) and dy-
namic range of detection (13 orders of magnitude on log  2   
scale of   Fig. 4  ), our results demonstrate that MHC I peptides 
derived preferentially, but not exclusively, from highly abun-
dant mRNAs. 
  Evidence that the MIP repertoire of thymocytes conceals
a tissue-specifi  c signature 
  Because MHC I peptides derived preferentially from highly 
abundant mRNAs, and abundance of discrete mRNAs varies 
among diff  erent tissues and organs, we hypothesized the MIP 
repertoire might harbor a tissue-specifi  c signature. Using the 
SymAtlas database (http://symatlas.gnf.org/SymAtlas/) (  50  ), 
we analyzed the relative expression in 58 mouse tissues of 
mRNAs encoding thymocyte MHC I  –  associated peptides 
(see Materials and methods for details on calculation). Re-
markably, the mean expression of the 180 mRNAs coding 
We therefore conclude that peptides obtained by MAE can 
be categorized as MHC I  –  associated versus contaminant pep-
tides with 1  –  3% false-positive and -negative rates using pub-
licly available algorithms. 
  Global portrayal of the MIP repertoire of primary
mouse thymocytes 
  In the next series of experiments, peptides eluted from pri-
mary mouse thymocytes by MAE were analyzed by on-line 
2D-nanoLC-MS/MS. Of the sequenced peptides, 189 were 
classifi   ed as MHC I associated based on the smm, SYF-
PEITHI, and Rankpep thresholds selected above: 84 H2D  b  -, 
91 H2K  b  -, 13 Qa2-, and 1 Qa1-associated peptides (Table 
S3, available at http://www.jem.org/cgi/content/full/jem
.20071985/DC1). Based on analyses described in the previ-
ous paragraph, we estimate that the false-positive rate for the 
189 thymocyte peptides is   <  2%. GO term enrichment analy-
sis was performed on the 189 genes coding for those peptides 
by applying stringent criteria from 772 functional annotations 
(  Fig. 4 A  ).   In accordance with a study on HLA-B*1801  –
    associated peptides (  25  ), the MIP repertoire of primary thy-
mocytes showed a modest but signifi  cant twofold enrichment 
in proteins located in the cytoplasm and the nucleus. More 
interestingly, we found an 11  –  19-fold enrichment in proteins 
related to cyclin and cyclin-dependent kinases (Ccng1, Cdkn1b, 
Chek1, Bccip, Cul2, Ccnd3, and CcnF), which regulate the 
cell cycle. We also found an 11  –  17-fold enrichment in heli-
cases (Dhx15, Ddx5, Ddx6, Hells, and Ddx47), which are 
required for effi   cient and accurate replication, repair, and re-
combination of the genome. 
  MHC I  –  associated peptides derive preferentially from highly 
abundant mRNAs 
  We next sought to determine whether the MIP repertoire of 
thymocytes was molded at the mRNA level. To this end, 
we compared the relative abundance of two sets of thymic 
    Figure 3.         Discrimination between MHC I  –  associated peptides and contaminant peptides using bioinformatic tools.   (A – E)  For  peptides  eluted 
from EL4 cells, the y axis shows computed MHC binding scores determined with the smm (A and C), SYFPEITHI (B and D), and Rankpep (E) computational 
methods. The x axis cut at the selected binding thresholds. Each bar represents a sequenced peptide. Individual H2D  b -,  H2K b  -, and Qa2-associated pep-
tides (red) and contaminant peptides (blue) were scored as illustrated.     JEM VOL. 205, March 17, 2008 
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that tissue-specifi  c expression is indicative of gene function in 
mammals (  51  ), we noted that hematolymphoid genes repre-
sented in the thymocytes  ’   MIP repertoire play critical roles 
in T cell development. For example,   Rhoh   is important for 
positive thymocyte selection,   Cxcr4   for migration of T cell 
progenitors, and   CD3e   for migration of T cell development 
(  53  –  55  ). Further studies are needed to cogently assess the 
functional importance of genes that impart tissue specifi  city 
to the thymocytes  ’   MIP repertoire. However, evidence sug-
gests that many, if not all, of these genes are functionally im-
portant for thymocyte function. In conclusion, two major 
and related points can be made regarding the connection be-
tween the transcriptome and the MIP repertoire. First, the 
MIP repertoire is enriched in peptides derived from highly 
abundant transcripts. Second, our data suggest that thymo-
cytes  ’   MIP repertoire conceals a tissue-specifi  c signature that 
derives from     17% of MHC I  –  associated peptides. 
  The MIP repertoire of normal versus neoplastic thymocytes 
  Ultimately, the genesis of MHC I peptides must be regulated by 
mRNA translation and protein degradation by the proteasome 
(  2, 49  ), two processes that are profoundly perturbed in neoplas-
tic cells (  56, 57  ). To evaluate the impact of neoplastic transfor-
mation on the MIP repertoire, we compared the MIP repertoire 
of primary thymocytes from C57BL/6 female mice to that of 
neoplastic thymocytes. As a source of neoplastic thymocytes, we 
used in vivo grown EL4 cells. EL4 cells were originally de-
rived from a C57BL/6 female mouse. Based on aforementioned 
experiments on the reproducibility of estimation of peptide 
thymocyte MHC I peptides was higher in the thymus than in 
all other tissues and organs (  Fig. 5 A  ).   
  Large-scale quantitative analyses of transcriptional expres-
sion profi  les across diff  erent tissues have revealed broadly ex-
pressed and tissue-specifi  c groupings (  50, 51  ). To determine 
whether the MIP repertoire of thymocytes is imprinted by 
tissue-specifi  c genes, we attributed a z score to individual 
source mRNAs (  52  ). Genes with high z score (from     2.5 to 7) 
correspond to those that are preferentially overexpressed 
in the thymus. Among the 180 genes encoding thymocyte 
MHC I peptides, 30 showed a high z score (  Fig. 5, B and C  ). 
The z score distribution of genes encoding thymocyte MHC I 
peptides is illustrated in   Fig. 5 B  , and a heat map representa-
tion of the 30 genes with high z scores is depicted in   Fig. 5 C  . 
Next, we estimated how additive removal of high z score 
genes would aff  ect the thymus specifi  city of the gene set. 
Thymus specifi  city of the gene set was lost after removal of 
the 30 high z score genes (  Fig. 5 D  ). In contrast, removal of 
up to 70 random genes did not aff  ect the thymus specifi  city 
of the gene set. These results suggest that the MIP repertoire 
of thymocytes conceals a tissue-specifi  c signature that is con-
stituted by     30 genes, i.e.,     17% of genes that are repre-
sented in the thymocytes  ’   MIP repertoire. 
  Among the 30 genes with high thymic z score, 16 are ex-
pressed, albeit at lower levels than in other organs, whereas 
14 genes are expressed almost exclusively in hematolymphoid 
organs:   Rhoh  ,   Centb1  ,   Cxcr4  ,   Depdc1a  ,   Foxp1  ,   Dnmt1  , 
  9230105E10Rik  ,  Cd3e  ,  C330027C09Rik  ,  Igtp  ,  Mns1  ,  Dock2  , 
  Actr2  , and   Vps13d   (  Fig. 5 C  ). In accordance with the concept 
    Figure 4.         Analyses of genes and transcripts coding MHC I  –  associated peptides eluted from primary thymocytes  . (A) GO term enrichment 
analysis of 189 genes coding MHC I peptides eluted from thymocytes. Exact P values and global false-discovery rates were   <  0.05 for each listed GO term. 
Values in parentheses indicate the fold enrichment relative to the whole mouse genome. (B) We compared the relative abundance of two sets of thymic 
transcripts using previously reported microarray data (  50  ): mRNAs coding MHC I peptides eluted from primary thymocytes (red), and 36,182 thymus-
derived transcripts (gray). Original mRNA expression data on the x axis were plotted on a log  2   scale. The y axes represent the number of transcripts for 
each sample set. (C) Frequency distributions for the two sets of thymic transcripts defi  ned in B were plotted using a bin increment of 0.2. Three distinct 
mRNA expression groups are shown (low-, medium-, and high-abundance mRNA). Graph shows the proportion of mRNAs with low- (black), medium- 
(red), and high- (blue) abundance among the two sets of transcripts. *, P   <   0.05; **, P   <   0.0001. (D) Predicted MHC binding score (determined with smm) 
for peptides whose mRNA are expressed at low, medium, or high level. Spearman linear correlation coeffi  cient (  r  ) was calculated for H2K  b -  (dashed  line; 
white squares) and H2D  b  -associated (solid line; black squares) peptides.     602 GENESIS OF THE MHC CLASS I PEPTIDE REPERTOIRE | Fortier et al.
regulated 3 (  Xlr3a/b  ) gene encoded a peptide found only on 
EL4 cells (  Fig. 6 B   and   Table II  ).   Xlr   genes are important for 
T cell diff  erentiation and are overexpressed in several lymphoid 
malignancies (  58  ). In contrast, an MHC I peptide from cyclin-
dependent kinase inhibitor 1B (  Cdkn1b  ) was underexpressed on 
neoplastic cells (  Fig. 6 C  ,   Table II  ).   Cdkn1b   is known to act 
as a potent tumor suppressor gene in a variety of cancers (  57  ). 
Remarkably,     50% of diff  erentially expressed peptides derived 
from genes that are known to be involved in tumorigenesis 
(  Table II   and Table S5). For example, 10 diff  erentially expressed 
peptides (  Bach2  ,   Cdkn1b  ,   Cxcr4  ,   Eif3s2, Eif3s10  ,   Igtp  ,   Pa2g4  , 
  Pi3kap1  ,   Ptpn6  , and   Sgk  ) originated from genes related to the 
PI3K  –  AKT  –  mTOR pathway, which is the oncogenic signal-
ing pathway most commonly targeted by genomic aberrations 
in cancer (  59, 60  ). 
abundance by MS analyses (Fig. S1), peptides were considered 
to be diff  erentially expressed when the fold diff  erence in abun-
dance was   ≥  2.5 (P   <   0.05). Table S3 and S4 (available at http://
www.jem.org/cgi/content/full/jem.20071985/DC1) present 
the complete list of peptides eluted from primary thymocytes 
and in vivo grown EL4 cells and their computed MHC binding 
score. Overall, 25% of MHC I peptides were diff  erentially ex-
pressed on normal versus neoplastic thymocytes (  Table II   and 
  Fig. 6 A  ).   Thus, 22 peptides were underexpressed and 21 were 
overexpressed on neoplastic relative to normal thymocytes 
(  Table II  ). Diff  erentially expressed peptides derived from genes 
implicated in several biological processes, such as cell cycle pro-
gression, apoptosis, signal transduction, cytoskeleton assembly, 
and diff  erentiation, as well as regulation of transcription and 
translation ( Table II ). As an example, the X-linked lymphocyte-
    Figure 5.         Peptide source mRNAs expression patterns reveal an organ-specifi  c signature in the MIP repertoire of thymocytes.   (A)  Comparison 
of normalized mean expression values (y axis) across 58 different tissues (x axis) including the thymus (red). Normalized mean expression values were 
calculated as follows: mean expression value from 180 peptide source genes/mean expression value of 36,182 transcripts for each particular tissue. 
Calculated values were ranked from left to right in a decreasing order. (B) Z scores were calculated for each of the 180 peptide source genes to identify 
transcripts preferentially expressed in the thymus. Graph shows frequency distributions of calculated z scores with a bin increment of 0.05. (C) Heat map 
shows the relative mRNA expression in 58 tissues of the 30 peptide source genes with highest thymic z scores. (D) High z score genes determine the thy-
mus specifi  city of the gene set encoding MHC I  –  associated peptides. Genes preferentially overexpressed in the thymus (high thymic z scores; blue) were 
additively removed (x axis). Normalized mean expression values and thymus rank (y axis) were determined following removal of each individual gene. 
Removal of the 30 genes with a high thymic z score had a drastic impact on thymus rank. Removal of up to 70 randomly selected genes (100,000 permu-
tations; green) had no signifi  cant impact on thymus rank.     JEM VOL. 205, March 17, 2008 
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salient fi  nding here is that 74% (14 of 19) of peptides over-
expressed on EL4 cells would have been missed by studies of 
mRNA expression levels. An important implication is that, 
at least in our model, overexpression of MHC I  –  associated 
peptides on neoplastic cells generally entails posttranscrip-
tional mechanisms. 
  Testing the immunogenicity of peptides overexpressed
on neoplastic cells 
  Finally, we wished to determine whether peptides overex-
pressed on neoplastic thymocytes (in vivo grown EL4 cells) 
would be able to elicit specifi  c CD8 T cell response. To test 
this, we used the following two peptides: (a) STLTYSRM, 
which is derived from serum/glucocorticoid-regulated kinase 
(Sgk) and presented by H2K  b  , and (b) VAAANREVL de-
rived from X-linked lymphocyte-regulated 3 (Xlr3a/b) and 
presented by H2D  b  . One important diff  erence between the two 
peptides is that VAAANREVL was not found on primary 
thymocytes (fold diff  erence relative to EL4 cells  ≥   85), whereas 
low levels of STLTYSRM were present on primary thymo-
cytes (fold diff  erence = 10;   Table II   and Table S6, available at 
http://www.jem.org/cgi/content/full/jem.20071985/DC1). 
TAP-defi  cient T2-D  b   and T2-K  b   cells were fi  rst incubated 
with titrated amounts of synthetic peptides to evaluate their 
  Genesis of peptides overexpressed on tumor cells 
  An important question is whether diff  erential expression of 
MHC I peptides on neoplastic relative to normal thymocytes 
correlates with changes in mRNA levels of source transcripts. 
To test this, we selected 19 peptides overexpressed on EL4 
cells relative to primary thymocytes, 15 that were under-
expressed, and 13 that were not diff  erentially expressed. Then, 
we analyzed the level of expression of their source mRNAs 
in neoplastic versus primary thymocytes using quantitative 
real-time PCR. Scatterplot representation of the correlation 
between relative mRNA expression and relative MHC I 
peptide expression is depicted in   Fig. 6 D  . From the linear 
regression, a Spearman coeffi   cient of 0.63 was calculated, 
showing a signifi  cant but moderate correlation between pep-
tide and mRNA expression ratios. The strength of the corre-
lation was conspicuously decreased by a set of 14 peptides 
that were more abundant on neoplastic cells, but whose 
mRNA levels were not overexpressed (  Fig. 6 D  , dotted box). 
Exclusion of these 14 genes increased the correlation coeffi   -
cient to 0.78. Remarkably, for the 19 peptides overexpressed 
on EL4 cells, increased transcript levels were present in EL4 
cells in only 5 cases (  Fig. 6 D  ). Peptides overexpressed on 
neoplastic cells are particularly important because they can be 
used as targets in cancer immunotherapy (  61, 62  ). Thus, the 
    Figure 6.         Relative quantifi  cation of differentially expressed MHC I peptides and source mRNAs from thymocytes and EL4 cells  . (A) Volcano 
plot representation illustrates MHC I peptides reproducibly detected across biological replicates (  n   = 3). Peptides over- and underexpressed on EL4 cells 
relative to thymocytes (P   ≤   0.05; fold change   ≥   2.5) were highlighted in blue and red, respectively. MS/MS spectra of circled peptides are shown in B and C. 
(B and C) Illustration of two differentially expressed MHC I peptides. Reconstructed ion chromatograms show differential abundance for m/z 471.77  2+  
(VAAANREVL) and 521.26  2+   (FGPVNHEEL) in EL4 cells versus thymocytes. MS/MS spectra confi  rm MHC I peptide sequences and the identifi  cation of the 
cognate source proteins. (D) Scatter plot shows the correlation between relative expression of mRNA and that of MHC I peptide. Expression ratios for 
source mRNA (x axis) and MHC I peptide (y axis) between EL4 cells and thymocytes were plotted on a log  2   scale for 47 pairs. A Spearman correlation co-
effi  cient was calculated from the linear regression. MHC I peptides overexpressed in EL4 cells or normal thymocytes are highlighted in blue and red, 
  respectively; peptides that were not differentially expressed are shown in gray. Dashed box shows peptides whose overexpression on EL4 cells did not 
correlate with increased mRNA levels of their source protein.     604 GENESIS OF THE MHC CLASS I PEPTIDE REPERTOIRE | Fortier et al.
    Table II.        Peptides differentially expressed on EL4 cells versus primary thymocytes 
Functional 
classifi  cation
Gene symbol Gene ID Function Sequence P value EL4/ 
  Thy
Transcription   Pa2g4      a   18813 Growth  regulation AQFKFTVL 0.02 4.6
  Top2a      a     21973 DNA  topoisomerase NSMVLFDHV 0.02 15.6
  Dnmt1      a     13433 DNA  methylation LSLENGTHTL 0.02 8.9
  Pfdn5      a     56612 Protein  binding/Folding SMYVPGKL 0.04 16.6
  Per1      a     18626 Transcription  regulator YTLRNQDTF 0.04 5.0
  Foxp1      a   108655 Transcription  factor QQLQQQHLL 0.01     4.3
  Bach2      a   12014 Transcription  factor EQLEFIHDI 0.02     20.2
  Pbrm1 66923 DNA  binding SQVYNDAHI 0.02     3.5
  Ddx5      a     13207 RNA  helicase NQAINPKLLQL 0.02     5.7
  Jhdm1d 338523 Histone  demethylase SSIQNGKYTL 0.02     4.9
Cell differentiation   Ptpn6      a      15170 Key role in hematopoiesis AQYKFIYV 0.03 3.3
  Mark2  13728 Maintenance of cell polarity ASIQNGKDSL 0.03 2.7
  Pi3kap1      a      83490 Role in BCR-mediated Pi3K activation YGLKNLTAL 0.001     21.8
  Xlr3a/b  22446 Role in lymphocyte development VAAANREVL 0.02 84.9
  RhoH      a      74734 Small GTPase/thymocyte maturation YSVANHNSFL 0.02     3.1
Cell cycle   Rcc2  108911 Required in mitosis and cytokinesis AAYRNLGQNL 0.04 27.0
  Cdkn1b      a      12576 Involved in G1 arrest FGPVNHEEL 0.003     3.1
Apoptosis   Sgk      a    20393 Response to DNA damage stimulus STLTYSRM 0.02 9.7
  Pdcd10      a    56426 Role in apoptotic pathways ILQTFKTVA 0.001     4.3
Signal transduction   Cxcr4      a      12767 Receptor for the chemokine 
 CXCL12/SDF1
VVFQFQHI 0.003 2.6
  CD97      a      26364 Involved in adhesion and signaling 
process
KLLSNINSVF 0.03     4.6
Translation   Eif3s10      a      13669 Translation initiation factor QSIEFSRL 0.02 3.2
  Eif3s2      a      54709 Translation initiation factor FGPINSVAF 0.04 5.3
Transport   Tmed9  67511 Intracellular protein transport VIGNYRTQL 0.02     6.9
  Copb1  70349 ER to Golgi vesicle-mediated transport IALRYVAL 0.01 2.9
Cytoskeleton   Tmod1 21916 Cytoskeleton  organization SSIVNKEGL 0.004 10.5
  Mylc2b  67938 Cytoskeleton organization and biogenesis SLGKNPTDAYL 0.01 4.2
  Mns1  17427 Involved in cell division and motility KIIEFANI 0.01     12.4
  Krt5  110308 Strutural constituent of cytoskeleton AAYMNKVEL 0.04     106.7
  Krt7  110310 Strutural constituent of cytoskeleton AAYTNKVEL 0.003     121.5
Miscellaneous   Igtp      a   16145 IFN    -induced GTPase IVAENTKTSL 0.001     15.5
  Nup205  70699 Outer membrane exporter porin VNNEFEKL 0.005     4.6
  Dhx15      a     13204 RNA  helicase TLLNVYHAF 0.02     11.5
  Stk11ip 71728 Serine/Threonine  kinase SALRFLNL 0.01     3.9
  Pde2a 207728 Catalytic  activity IKNENQEVI 0.02 16.0
  Gtpbp4      a     69237 GTP  binding QILSDFPKL 0.03 2.6
  Narfl   67563 Prelamin  recognition VAYGFRNI 0.01 8.7
  Rmnd5a  68477 Hypothetic role for meiotic nuclear 
 division
WAVSNREML 0.02     6.2
Unknown   Specc1 432572 TSLAFESRL 0.01 7.1
  Ccdc41 77048 AQVENVQRI 0.01     2.8
  2900073G15Rik 67268 SMGKNPTDEYL 0.05 3.8
  D14Ertd436e 218978 SQHVNLDQL 0.04     2.7
  9230105E10Rik 319236 FISDVEHQL 0.01     23.2
Gene ID and Gene Symbol description refer to National Center for Biotechnology Information gene entries. Fold change and P values were calculated from biological replicate 
experiments (  n   = 3). Functional classifi  cation is based upon bibliographic searches.
  a    Genes that are involved in neoplastic transformation (see Table S6 [available at http://www.jem.org/cgi/content/full/jem.20071985/DC1] for references).JEM VOL. 205, March 17, 2008 
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not require diff  erent purifi  cation steps, higher sensitivity can 
be achieved from limiting the amount of materials compared 
with chemical derivatization where peptide recovery can be 
aff  ected by variable modifi  cation yields or side reaction prod-
ucts (  31  ). Thus, by combining our MS strategy with MAE, 
we were able to generate a comprehensive portrayal of the 
MIP repertoire of EL4 cells from   <  10  8   cells. The ability to 
identify large numbers of MHC I peptides from limiting 
amounts of cells is a noteworthy advantage. Moreover, our 
quantifi  cation method can be used to analyze any type of cell 
population, whereas metabolic labeling strategies can only be 
applied to cell culture model systems. Nevertheless, low abun-
dance peptides (  <  100 copies/cell) remain challenging to identify 
in view of the sensitivity of present high-throughput, MS-based 
methods. The portrayal of the MIP repertoire described in this 
study and others is far from complete, and low-abundance 
peptides that may be biologically relevant could remain elusive 
to current detection methods. 
  We took advantage of EL4 variant cell lines (WT,     2m        
mutant, and     2m  +   transfectant) to unambiguously discrimi-
nate between MHC I  –  associated peptides and contaminants 
in peptide mixtures obtained by MAE. A large proportion of 
contaminants was made of long peptides derived from the 
C-terminal end of source proteins (unpublished data). We noted 
that some of these contaminants have previously been con-
sidered as MHC I  –  associated peptides in studies where pep-
tides were obtained by MAE or immunoaffi   nity purifi  cation 
(  23, 63  ). The need to have an MHC I  –  defi  cient negative 
control to distinguish MHC I peptides from contaminants 
would be a cumbersome limitation for analysis of primary 
cells. However, we showed that the use of computational 
models such as SYFPEITHI and smm obviated this need. 
Thus, thresholds used herein yielded false-positive and -negative 
rates of     2% in identifi  cation of MHC I peptides. 
  The MIP repertoire of primary cells 
  High-throughput analysis of peptides obtained by MAE pro-
vided us with a global portrayal of peptides presented by dif-
ferent MHC I allelic products (in this study: H2D  b  , H2K  b  , 
Qa1, and Qa2). We found that, with rare exceptions, discrete 
MHC I molecules presented peptides derived from diff  erent 
sets of source proteins (Table S2 and S3). A corollary is that 
expression of multiple MHC I allelic products (a consequence 
of gene duplication and diversifi  cation [  64  ]) favors represen-
tation of largely nonoverlapping sets of source proteins in the 
MIP repertoire. By integrating global profi  ling of the mouse 
protein-encoding transcriptome (  50  ) with the MIP repertoire 
of thymocytes, we found that the thymocytes  ’   MIP reper-
toire is enriched in peptides derived from highly abundant 
transcripts. Furthermore, our data suggest that the repertoire 
of MHC I  –  associated peptides conceals a tissue-specifi  c sig-
nature that derives from     17% of genes represented in the 
MIP repertoire. Cogent evaluation of this exciting concept will 
require comprehensive analyses of MHC I  –  associated peptides 
eluted from various tissues and organs. Why would the MIP 
repertoire show a stronger correlation with the transcriptome 
ability to bind and stabilize H2K  b   and H2D  b  . In contrast to 
the L  d  -restricted peptide RPQASGVYM, both STLTYSRM 
and VAAANREVL peptide loading resulted in an increase in 
cell surface expression of H2-K  b   or H2-D  b   (Fig. S2), thereby 
confi  rming their ability to bind their respective MHC allele. 
We next immunized C57BL/6 mice with DCs coated or not 
coated with VAAANREVL and STLTYSRM synthetic pep-
tides. Splenocytes from immunized mice were tested for in 
vitro cytotoxicity against primary thymocytes and EL4 target 
cells that were not loaded with exogenous peptides. Spleno-
cytes from mice primed with unloaded DCs showed no cyto-
toxic activity. In contrast, splenocytes primed with coated 
DCs killed EL4 cells, but not primary thymocytes (  Fig. 7  ).   
Thus, peptides overexpressed by 10- to   ≥  85-fold on neoplastic 
cells elicited specifi  c cytotoxic activity against endogenously 
presented epitopes. 
    DISCUSSION   
  We have developed a novel method for high-throughput 
analysis of MHC I peptides and performed a comprehensive 
study of the MIP repertoire of normal and neoplastic thymo-
cytes. Our studies yielded important insights into the genesis 
of the MIP repertoire and how it is modifi  ed by neoplastic 
transformation. 
  A novel method for high-throughput, MS-based analysis
of MHC I peptides 
  In the last few years, high-throughput screening methods 
coupled with bioinformatics tools have helped to fi  gure out 
the complexity of biological matrices. Thus, emerging tech-
nologies in mass spectrometry have led to the development 
of peptide detection algorithms that can be used, in combina-
tion with segmentation analyses, to compare unlabeled peptide 
populations (unpublished data) (  36  ). This powerful approach 
allowed us to obtain an accurate quantifi  cation of native un-
labeled MHC I peptides without any chemical or metabolic 
labeling modifi  cations. Because preparation of samples does 
    Figure 7.         Splenocytes primed against peptides overexpressed on 
EL4 cells selectively kill EL4 cells  . Mice were immunized with DCs coated 
with STLTYSRM (A) or VAAANREVL (B) peptide. Splenocytes from primed 
mice were restimulated in vitro with the corresponding peptide for 6 d, and 
tested for in vitro cytotoxic activity against CFSE-labeled target cells (EL4 
cells and primary mouse thymocytes) at different E/T ratios. Number of 
effectors represents the number of unfractionated splenocytes used in the 
cytotoxicity assay. Mice immunized with unloaded DCs were used as nega-
tive control. Data represent the mean   ±   the SD for four mice per group.    606 GENESIS OF THE MHC CLASS I PEPTIDE REPERTOIRE | Fortier et al.
corresponding MHC I peptides in normal and neoplastic thy-
mocytes (  Fig. 6 D  ; r = 0.63). We surmise that the stronger 
correlation in our case may be caused by estimation of tran-
script levels with quantitative real-time PCR analyses rather 
than microarrays. Indeed, quantitative real-time PCR pro-
vides a more accurate estimation of quantitative diff  erences 
than microarrays (  66  ). However, our data support the main 
conclusion of Weinzierl et al., which is that a majority of 
peptides overexpressed on neoplastic cells (74% in our case) 
would have been missed by estimation of transcript levels. 
Together with data from Weinzierl et al., our results suggest 
that in general, overexpression of MHC I peptides on neo-
plastic cells is caused by posttranscriptional mechanisms and 
can be detected only by MS-based expression profi  ling ap-
proaches. Further studies on diverse cancer types are needed 
to test the generality of these observations. Relevant mecha-
nisms may include dysregulation of microRNA expression, 
protein translation, and proteasomal degradation (  67  –  69  ). 
  Our data suggest that the MIP repertoire gives a unique 
perspective into the mechanisms of carcinogenesis. Approx-
imately 50% of peptides diff  erentially expressed on normal ver-
sus neoplastic cells are coded by genes involved in neoplastic 
transformation (  Table II   and Table S5). It is quite remark-
able that 10 of the diff  erentially expressed peptides derived 
from genes related to the PI3K  –  AKT  –  mTOR pathway. The 
PI3K  –  AKT  –  mTOR pathway is the most prominent path-
way regulating protein translation, cell growth, and cell pro-
liferation, and is activated in most cancers (  59  ). In addition, 
our data lead us to speculate that the MIP repertoire might 
give unique insights into acquired epigenetic abnormalities 
that are so important in cancer. Indeed,   Dnmt1  , which regu-
lates DNA methylation and prevents genomic instability (  70  ), 
is expressed at high levels in thymocytes (  Fig. 5 C  ). We found 
that a   Dnmt1  -derived peptide was overexpressed     9-fold on 
neoplastic relative to primary thymocytes (  Table II  ). This raises 
the enticing possibility that enhanced proteasomal degrada-
tion of Dnmt1 might be responsible for the genomic instabil-
ity of EL4 cells. Finally, we were able to generate specifi  c 
cytotoxic T cell responses against EL4 cells by priming WT 
mice with two peptides overexpressed on EL4 cells (  Fig. 7  ). 
The fi  nding that effi   cient cytotoxic responses could be elic-
ited against endogenously expressed tumor peptides identi-
fi  ed with our MS-based expression analyses validates the 
analytical potential of the present approach. Though further 
work is needed to evaluate the therapeutic value of vaccina-
tion with these peptides, our results strongly support the con-
cept that high-throughput analysis of the MIP repertoire is a 
promising discovery platform for the identifi  cation of immuno-
genic tumor-associated peptides (  27, 61, 62  ). 
    MATERIALS AND METHODS   
  Chemicals and materials.     Citric acid, aprotinin, iodoacetamide, and 
  sodium phosphate dibasic (Na  2  HPO  4  ) were purchased from Sigma-Aldrich; 
high-performance liquid chromatography  –  grade water, methanol (MeOH), 
and acetonitrile were obtained from Thermo Fisher Scientifi  c; formic acid 
(FA) and ammonium acetate were purchased from EM Science; fused-silica 
(this study) than the proteome (  28  )? Probably because the 
proteome is enriched in slowly degraded proteins (with a 
mean   t    1/2   of   >  1,000 min), whereas the MIP repertoire origi-
nates mainly from rapidly degraded proteins (with a mean   t    1/2   
of     10 min) that have recently been translated and degraded 
(  28, 49  ). In other words, MHC I molecules sample what is 
being translated rather than what has been translated (  49  ). 
Considering the pervasive roles of MIPs, particularly in CD8 
T cell development and function, it will be extremely inter-
esting to determine whether the MIP repertoire of specialized 
cell types does conceal a tissue-specifi  c signature. Of particu-
lar interest are thymus cortical epithelial cells, which support 
thymocyte positive selection, and thymus medullary epithe-
lial cells, which express promiscuous transcripts involved in 
tolerance induction. Besides, although the MIP repertoire is 
enriched in peptides derived from highly abundant mRNAs, 
some peptides presented by MHC class I molecules derive from 
low abundance mRNAs (  Fig. 4  ). How can low-abundance 
transcripts successfully compete with more abundant tran-
scripts for representation in the MIP repertoire? Attractive 
possibilities would be that successful transcripts generate 
more DRiPs than others or that they are translated by spe-
cial   “  immunoribosomes  ”   (  33, 49  ). 
  The proteasome, which is the primary source of MHC I 
peptides, is much more ancient than the MHC. The MHC 
appeared in gnathostomes, whereas proteasomes are found in 
all eukaryotes. Fundamental functions of the proteasome are 
to regulate cell cycle, proliferation, and apoptosis (  65  ). In line 
with this, we found that the MIP repertoire of primary thy-
mocytes was enriched in peptides derived from cyclins, cyclin-
dependent kinases, and helicases (  Fig. 4 A  ). These highly 
conserved proteins regulate cell proliferation, cell cycle arrest, 
and apoptosis. Peptides derived from cyclin, cyclin-dependent 
kinase, and helicase gene families have also been found in 
other studies of MHC I peptides (  9, 25, 63  ). We surmise that 
the presence of these peptide families in the MIP repertoire 
may represent an imprint of primordial functions of the pro-
teasome. Nevertheless, an alternative hypothesis would be that 
overrepresentation of peptide-derived proteins regulating 
proliferation and apoptosis is a thymocyte-specifi  c feature be-
cause thymocytes display particularly high rates of prolifera-
tion and apoptosis. 
  The MIP repertoire of neoplastic cells 
  Neoplastic transformation is associated with many genomic 
and proteomic changes. How these changes may impinge on 
the MIP repertoire and thereby be perceived by CD8 T cells, 
is a fundamental question in cancer immunology that can be 
addressed directly only by MS-based analysis of the MIP rep-
ertoire. Weinzierl et al. recently reported a seminal study in 
which they integrated mass spectrometry and microarray data 
on renal cell carcinomas and autologous normal kidney tis-
sues (  9  ). They found a poor correlation between changes in 
peptide expression and changes in the abundance of mRNA 
levels in normal versus cancer cells (  r   = 0.32). We found a 
better correlation between mRNA levels and expression of JEM VOL. 205, March 17, 2008 
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ions were selected for MS/MS sequencing. Tandem MS experiments were 
performed using collision-induced dissociation in the linear ion trap (IT mode). 
Target ions already selected for MS/MS fragmentation were dynamically 
excluded for 80 s, and a minimal intensity value of 10,000 was fi  xed for pre-
cursor ion selection. 
  Peptide detection and clustering.     Raw data fi  les generated from the 
Orbitrap were processed using in-house peptide detection software (Mass Sense) 
to identify all ions according to their corresponding m/z values, charge state, 
retention time, and intensity. From this process, lists of detected peptides 
ions were generated to defi  ne individual LC-MS analysis. A user-defi  ned in-
tensity threshold above the background noise (typically between 5,000 and 
15,000) was fi  xed to limit false-positive identifi  cation. Segmentation analyses 
were performed across sample sets using hierarchical clustering to generate 
lists of nonredundant peptide clusters (  35  ). User-specifi  ed tolerances were 
fi  xed to, typically,   ±  0.04 m/z,   ±  1.5 min, and   ±  1 fraction for 2D-LC-MS 
Orbitrap experiments. Identifi  cation fi  les from Mascot were converted in 
Excel format (Microsoft), and sequenced peptides were aligned with their 
corresponding peptide clusters using in-house clustering software. 
  MS/MS sequencing and protein identifi  cation.     The data were searched 
against International Protein Index mouse database using the Mascot (Matrix 
Science) search engine. The mass tolerance on precursor and fragment ions 
was set to   ±  0.1 and   ±  0.4 Daltons, respectively. Searches were performed 
without enzyme specifi  city. All relevant hits were inspected manually for 
mass accuracy and to validate sequence assignment according to the observa-
tion of consistent b- and y-types fragment ion series. From MHC I peptide 
structures identifi  ed, 85% were sequenced at least twice across replicate 
  injections, and all had mass accuracy within 30 ppm of the theoretical values 
(without the use of a lock mass). To estimate the false-positive rate across 
non  –  MHC I  –  associated peptide identifi  cation,     2m-defi  cient EL4 samples 
were searched against a concatenated forward/reverse International Protein 
Index mouse database to establish a cutoff   score threshold (  >  45) for a false-
positive rate of   <  2%. All identifi  ed MHC I peptides were blasted against 
nonredundant NCBInr (restricted to mouse entries) to identify their corre-
sponding source proteins (Gene ID). 
  Quantitative real-time PCR.     Freshly isolated thymocytes and EL4 cells 
were homogenized in TRIzol RNA preparation reagent (Invitrogen), and 
total RNA was isolated as instructed by the manufacturer. 1   μ  g of total RNA 
was converted to cDNA using random hexamer priming (Thermoscript 
RT-PCR System; Invitrogen). Gene expression level was determined using 
primer and probe sets from Universal ProbeLibrary (Table S7, available at 
http://www.jem.org/cgi/content/full/jem.20071985/DC1). PCR reac-
tions for 384-well plate formats were performed using 2   μ  l of cDNA samples 
(50 ng), 5   μ  l of the TaqMan PCR Master Mix (Applied Biosystems), 2   μ  M 
of each primer, and 1   μ  M of the Universal TaqMan probe in a total volume 
of 10   μ  l. The ABI PRISM 7900HT Sequence Detection System (Applied 
Biosystems) was used to detect the amplifi  cation level and was programmed 
to an initial step of 10 min at 95  °  C, followed by 40 cycles of 15 s at 95  °  C 
and 1 min at 60  °  C. All reactions were run in triplicate, and the mean values 
were used for quantifi  cation. The mouse GAPDH or 18S ribosomal RNAs 
were used as endogenous controls. 
  Microarray dataset cross comparison.     Normalized mRNA expression 
data (  50  ) (http://symatlas.gnf.org/SymAtlas/) used in this study were visual-
ized with TIGR MultiExperiment Viewer (http://www.tigr.org/software/
microarray.shtml). Normalized mean expression values were calculated as 
follows for each tissue: average expression value of 180 peptide source 
genes/average expression value of 36,182 transcripts. 
  Expression Analysis Systematic Explorer analysis and statistical 
methods.     The Expression Analysis Systematic Explorer (EASE) software (  75  ) 
was downloaded from the Database for Annotation, Visualization, and Inte-
grated Discovery (http://david.abcc.ncifcrf.gov/ease/ease.jsp) (  76  ). For gene 
capillaries were obtained from Polymicro Technologies; and Tefl  on and 
PEEK tubing were purchased from Supelco. The Jupiter Proteo C12 4     m 
material used for packing homemade precolumn and column was obtained 
from Phenomenex. Strong cation exchange (SCX) material was purchased 
from PolyLC. 
  Cell lines and fl  ow cytometry.     The EL4 (    2m  +   WT), C4.4-25        (    2m        
mutant), and E50.16  +   (    2m  +   transfectant of C4.4-25       ) cell lines were provided 
by R. Glas (Karolinska Institutet, Karolinska University Hospital, Huddinge, 
Sweden). T2-K  b   and T2-D  b   cell lines (gifts from S. Joyce, Vanderbilt Uni-
versity School of Medicine, Nashville, TN) were maintained as previously 
described (  71  ). MHC class I molecules at the cell surface were stained with 
PE-conjugated anti  –  H-2K  b   (clone AF6-88.5; BD Biosciences), FITC-con-
jugated anti  –  H-2D  b   (clone KH95; BD Biosciences), and biotin-conjugated 
anti  –  Qa-2 (clone 1  –  1-2; BD Biosciences) and analyzed on a BD LSR II fl  ow 
cytometer using FACSDiva software (BD Biosciences). 
  Peptide extraction and mass spectrometry analysis.     Freshly isolated 
thymocytes were obtained from 4  –  6-wk-old C57BL/6 female mice pur-
chased from The Jackson Laboratory. All mice were maintained under spe-
cifi  c pathogen  –  free conditions according to the standards of the Canadian 
Council on Animal Care. Experimental protocols were approved by the 
Comit  é   de D  é  ontologie Animale of the Universit  é   de Montr  é  al. Thymo-
cytes were separated from stroma according to standard procedures (  72  ). 
For isolation of EL4 cells grown in vivo, mice were injected intraperitone-
ally with 200,000 EL4 cells, and ascites fl  uid was harvested 17 d later. Purity 
of EL4 cells was assessed by fl  ow cytometry (  73  ). Three biological replicates 
were prepared and analyzed for normal thymocytes and EL4 cells. Cell sur-
face MHC I peptides were isolated from viable cells as previously described, 
but using a slightly modifi  ed protocol (  37  ). In brief, 4 ml of citrate-phosphate 
buff  er at pH 3.3 (0.131 M citric acid/0.066 M Na  2  HPO  4  , NaCl 150 mM) 
containing aprotinin and iodoacetamide (1:100) was added to each fl  ask, 
and cell pellets were resuspended by gentle pipetting for 1 min to denature 
MHC I complexes. Cell suspensions were then pelletted and the resulting 
super    natant was isolated. Peptides extracts were desalted using Oasis HLB 
cartridges (30 mg; Waters), and bound material was eluted with 1 ml H  2  O/80% 
MeOH/0.2% FA (vol/vol) and diluted to H  2  O/40% MeOH/0.2% FA 
(vol/vol). Peptides were then passed through ultrafi  ltration devices (Amicon 
Ultra; Millipore) to isolate peptides   <  5,000 Daltons and to remove     2m 
proteins. The resulting fl  owthrough was then lyophilized and stored at     30 
or     80  °  C until analysis. 
  To extract the equivalent amount of MHC I peptide from EL4 cells and 
normal thymocytes, we assessed the amount of MHC I molecules on both 
cell populations using previously described methods (  74  ). Equivalent amount 
of MHC I material from neoplastic (8   ×   10  7  ) and normal (2.3   ×   10  9  ) thymo-
cytes were separated by on-line 2D separation (SCX/C12 Jupiter Proteo 
4    m) using an Eksigent nanoLC-2D system. Samples were diluted in 
H  2  O/2% acetonitrile/0.2% FA before LC-MS analyses. The homemade 
SCX column (0.3 mm i.d.   ×   45 mm) was connected directly to the switch-
ing valve. During sample loading, the SCX column was positioned off  -line 
of C  12   precolumn to remove interfering species. Salt fractions (10   μ  l each) 
were loaded on SCX column at 5   μ  l/min for 6 min to sequentially elute 
peptides onto the C  12   precolumn using pulsed fractions of 0, 75, 300, and 
1,000 mM of ammonium acetate (pH 3.0). A 69-min gradient from 3  –  60% 
acetonitrile (0.2% FA) was used to elute peptides from a homemade reversed-
phase column (150     m i.d.   ×   100 mm) with a fl  ow rate set at 600 nanoliter/
min. On-line 2D-nanoLC-MS system was used to provide enhanced selec-
tivity, as well as a higher capacity to detect low-abundance MHC I peptides. 
To achieve high mass accuracy and sensitivity from a limited amount of 
starting material, abundance profi  les and tandem MS experiments were per-
formed simultaneously using a LTQ-Orbitrap mass spectrometer (Thermo 
Fisher Scientifi  c) equipped with a nanoelectrospray ion source (1.5  –  1.7 kV). 
MS scans were acquired in the FT mode (Orbitrap) with a resolution set at 
60,000 (m/z 400). Each full MS spectrum was followed by three MS/MS 
spectra (four scan events), where the three most abundant multiply charged 608 GENESIS OF THE MHC CLASS I PEPTIDE REPERTOIRE | Fortier et al.
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enrichment analysis, statistical and corrected P values were calculated from 
the Fisher exact test and the global false-discovery rate, respectively. 
  Z score transformation.     Raw intensity data for each tissue were log  2   
transformed and used for the calculation of z scores. Z scores were calculated 
by subtracting the overall average tissue intensity (for a single gene) from the 
raw intensity data within a given tissue, and dividing that result by the SD of the 
overall tissue intensities: z score = (intensity G  Th        mean intensity G  T1  …  T      n    )/
SD G  T1  …  T      n    , where G  Th   is any gene on the microarray from the thymus tissue 
and T1  …  T  n   represents the aggregate measure of all tissues. 
  Peptide-binding and in vitro cytolytic assay.     Peptides were synthesized 
by the Centre Hospitalier de l  ’  Universit  é   Laval Research Center (Quebec) 
and purifi  ed by high performance liquid chromatography (purity   >   90%). 
Rescue of class I expression in T2-D  b   and T2-K  b   cells by allele-specifi  c peptides 
was determined as previously described (  77  ). Bone marrow  –  derived DCs 
were generated as previously described (  78  ). On day 9 of culture, peptides 
were added at a concentration of 2   ×   10      6   M and incubated with DCs for 3 h 
at 37  °  C. For mouse immunization, 10  6   peptide-pulsed DCs were injected i.v. 
in C57BL/6 females at day 0 and 7. At day 14, splenocytes were harvested 
from the spleens of immunized mice and depleted of red blood cells using 
0.83% NH  4  CL. Cells were plated at 5   ×   10  6   cells/well in 24-well plates and 
restimulated with 2   ×   10      6   M peptide at 37  °  C. After 6 d, cytotoxicity was evalu-
ated by a CFSE-based assay (  79  ). The percentage of specifi  c lysis was calcu-
lated as follows: (number of remaining CFSE  +   cells after incubation of target 
cells alone      number of remaining CFSE  +   cells after incubation with eff  ector 
cells/number of CFSE  +   cells after incubation of target cells alone)   ×   100. 
  Online supplemental material.     Fig. S1 illustrates that 95% of peptide ions 
showed a variation of less than   ±  1.4- and   ±   2.2-fold in abundance across 
2D-nanoLC-MS instrumental and biological replicates, respectively. Fig. S2 
depicts experimental data that validate bioinformatic discrimination between 
MHC I  –  associated peptides and contaminant peptides. Table S1 shows the 
relative abundance of peptides eluted from WT,     2m       , and     2m  +   EL4 cell 
lines. Table S2 shows the computed MHC binding affi   nity of MHC I  –  asso-
ciated peptides eluted from EL4 cells. Table S3 shows the computed MHC 
binding affi   nity of MHC I  –  associated peptides eluted from primary mouse 
thymocytes. Table S4 shows the computed MHC binding affi   nity of MHC 
I  –  associated peptides eluted from in vivo grown EL4 cells. Table S5 is a list 
(with references) of cancer-related genes coding for MHC I peptides diff  er-
entially expressed in neoplastic (EL4) versus normal thymocytes. Table S6 
shows the relative abundance of MHC I  –  associated peptides eluted from 
primary thymocytes versus in vivo grown EL4 cells. Table S7 is a list of primers 
used for quantitative RT-PCR analyses. 
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